Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States

BACKGROUND: Oral semaglutide is the first orally administered glucagon-like peptide-1 receptor agonist (GLP-1RA) approved by the FDA. Clinical trials found that oral semaglutide 14 mg had a greater reduction in hemoglobin A1c (A1c) compared with empagliflozin 25 mg and sitagliptin 100 mg and was non...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Jiayu, Klepser, Donald G, McAdam-Marx, Carrie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391238/
https://www.ncbi.nlm.nih.gov/pubmed/34185562
http://dx.doi.org/10.18553/jmcp.2021.27.7.840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391238/
https://www.ncbi.nlm.nih.gov/pubmed/34185562
http://dx.doi.org/10.18553/jmcp.2021.27.7.840

Ejemplares similares